Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Launched by CHIAYI CHRISTIAN HOSPITAL · Jul 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of Xarelto (Rivaroxaban) to help prevent serious blood clots, known as venous thromboembolism, after patients undergo total hip or total knee replacement surgeries. Blood clots can be a common complication for patients in Taiwan following these procedures, and the trial aims to see if Xarelto is effective and safe for these patients. The researchers are looking for participants who are scheduled for either a total knee or total hip replacement and are between the ages of 20 and 7304.

If you decide to participate, you will be randomly assigned to either receive Xarelto or not, and the study will track the occurrence of blood clots and any related complications. It's important to note that individuals with certain conditions, such as recent blood clotting issues or who have taken blood-thinning medications lately, are not eligible to join. This trial is currently recruiting participants and aims to provide valuable information to improve care for patients undergoing hip and knee surgeries in Taiwan.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Undergo total knee replacement or total hip replacement
• Exclusion Criteria:
• • Recent antithrombotics use
• • A history of a coagulopathy
• • Recent thromboembolic disease
• • Preoperative deep vein thrombosis screening presents positive
• • Age below 20